Xcout IntelOpus Genetics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Opus Genetics, Inc. among biotechnology companies — ranked by similarity to what Opus Genetics, Inc. actually does, not by market-cap band.
Subscribe to see Opus Genetics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Opus Genetics, Inc. at a glance
Opus Genetics, Inc. is a biotechnology company headquartered in Durham, United States. It is publicly listed (IRD) with a market capitalisation of $378.2M. Xcout tracks 39 named people at Opus Genetics, Inc., including George Magrath (Chief Executive Officer & Director).
Opus Genetics, Inc. leadership
- George MagrathChief Executive Officer & Director
- Dr. George MagrathChief Executive Officer & Director
- Ben YerxaPresident
- Benjamin R. YerxaPresident & Director
- Joseph K. SchachleChief Operating Officer
- Joe SchachleChief Operating Officer
33 more named people on record for Opus Genetics, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Opus Genetics, Inc. competitors
Ranked by semantic similarity — how close each company is to Opus Genetics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
ONL Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in Michigan, United States, focused on the development of novel therapies for retinal diseases.
Biotech
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Similar biotechnology company
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Similar biotechnology company
OphRx is an Israeli biotechnology company founded in 2014 that specializes in developing noninvasive, topical drug delivery solutions for eye diseases utilizing lyotropic liquid crystals. The company is in the preclinical stage of developing novel treatments, including product candidates for front- and back-of-the-eye conditions.
Similar biotechnology company
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, with additional offices in Baltimore, Maryland, focused on developing medicines for ocular diseases.
Biotech
Operating primarily out of Australia, Opthea Limited is a clinical-stage biopharmaceutical firm dedicated to developing and marketing treatments for ophthalmic conditions. Its therapeutic pipeline leverages a robust intellectual property portfolio centered on Vascular Endothelial Growth Factors (VEGF) such as VEGF-C and VEGF-D, along with VEGF Receptor-3. This scientific foundation aims to address disorders characterized by abnormal blood and lymphatic vessel formation and excessive vascular leakage. The company's flagship product, OPT 302, is currently undergoing clinical trials. This soluble form of VEGFR-3 is being explored as a groundbreaking treatment for both wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Notably, OPT 302 functions as a novel VEGF-C/D inhibitor, intended to be administered alongside existing VEGF-A inhibitors to combat wet AMD and various other retinal disorders. Initially incorporated in 1984 as Circadian Technologies Limited, the company officially adopted the name Opthea Limited in December 2015. Its corporate headquarters are located in South Yarra, Australia.
Life Sciences
AsclepiX Therapeutics, Inc. is a biotechnology company incorporated in October 2018 in the United States. The company focuses on the discovery and development of peptide-based therapeutics for the treatment of retinal diseases and various types of cancer.
Biotech
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Biotech
Character Biosciences is a biotechnology company that uses human genetics and functional genomics to discover and develop precision medicines. Its work has focused particularly on genetically informed therapies for age-related diseases, including ophthalmic conditions such as age-related macular degeneration.
Similar biotechnology company
OcuCure Therapeutics, Inc. is an ophthalmic pharmaceutical company located in Virginia that focuses on developing new proprietary drugs at the intersection of medical research and healthcare solutions.
Biotech
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.
Biotech
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is advancing a range of medications designed for various ocular conditions, impacting both the anterior and posterior segments of the eye, such as dry eye disease, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. It was previously known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was established in 2017 and operates from its headquarters in Guangzhou, People's Republic of China.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Opus Genetics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Opus Genetics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →